Table 1 |
|||
|
Effector molecules induced by IL-17 from human cells |
|||
|
Molecule produced |
Cell source |
Major functional effects |
Reference |
|
|
|||
|
IL-1β |
FLS, Mono/Mac, Chond/OC |
Inflammation, fever, synergy with IL-17 |
[52,53,55,58] |
|
IL-6 |
FLS, Mono/Mac, Chond/OC |
Acute-phase reaction, B-cell stimulation, Th17 differentiation |
[51-53,58] |
|
IL-23 |
FLS |
Inflammation, Th 17 cell stimulation |
[56] |
|
TNF-α |
Mono/Mac |
Inflammation, synergy with IL-17 |
[52,53] |
|
CXCL1 (GRO-α) |
FLS, Chond/OC |
Leukocyte recruitment |
[55,60] |
|
CXCL5 (LIX) |
Chond/OC |
Leukocyte recruitment |
[60] |
|
CXCL8 (IL-8) |
FLS |
Leukocyte recruitment |
[51-53,55] |
|
CCL2 (MCP-1) |
FLS, Chond/OC |
Leukocyte recruitment |
[55,60] |
|
CCL20 (MIP-3α) |
FLS |
Leukocyte recruitment |
[54] |
|
G-CSF |
FLS |
Granulopoiesis |
[51] |
|
GM-CSF |
FLS |
Granulopoiesis |
[51–53] |
|
VEGF |
FLS, Chond/OC |
Angiogenesis |
[57,59] |
|
Cyclooxygenase-2 |
FLS, Mono/Mac, Chond/OC |
Inflammation |
[52,58] |
|
Prostaglandin E2 |
FLS, Mono/Mac, Chond/OC |
Inflammation |
[51–53] |
|
RANK/RANK ligand |
Chond/OC |
Osteoclastogenesis and bone resorption |
[53] |
|
Nitric oxide |
Chond/OC |
Tissue destruction |
[52,53,58] |
|
Matrix metalloproteinases |
Mono/Mac, Chond/OC |
Cartilage and tissue destruction |
[53,60] |
|
|
|||
|
Chond/OC, chondrocytes and osteoclasts; FLS, fibroblast-like synoviocytes; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-monocyte colony stimulating factor; GRO, growth-regulated oncogene; IL, interleukin; MCP, monocyte chemotactic protein; MIP-3α, macrophage inflammatory protein-3 alpha; Mono/Mac, monocytes and macrophages; RANK, receptor activator of nuclear factor-kappa B; TNF-α, tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor. |
|||
|
Lundy et al. Arthritis Research & Therapy 2007 9:202 doi:10.1186/ar2107 |
|||